Signaling pathways in the development of infantile hemangioma

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Ji, Yi ^a   Chen, Siyuan ^a   Li, Kai ^b   Li, Li ^a   Xu, Chang ^a   Xiang, Bo ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Angiogenesis; Infantile hemangioma; Neovascularization; Vasculogenesis

Indexed keywords

ANGIOGENESIS INHIBITORS; HEMANGIOMA; HUMANS; INFANT; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84893159492     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-13     Document Type: Review

References (123)

1. Vascular anomalies. Mulliken JB, Fishman SJ, Burrows PE, Curr Probl Surg 2000 37 8 517 584 10.1016/S0011-3840(00)80013-1 10955029
2. Hemangiomas in children. Drolet BA, Esterly NB, Frieden IJ, N Engl J Med 1999 341 3 173 181 10.1056/NEJM199907153410307 10403856 (Pubitemid 29325746)
3. Cutaneous hemangiomas in children. Diagnosis and conservative management. Margileth AM, Museles M, JAMA 1965 194 5 523 526 10.1001/jama.1965. 03090180047011 5897362
4. Adverse effects of systemic glucocorticosteroid therapy in infants with hemangiomas. George ME, Sharma V, Jacobson J, Simon S, Nopper AJ, Arch Dermatol 2004 140 8 963 969 15313812 (Pubitemid 39062647)
5. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma. Goyal R, Watts P, Lane CM, Beck L, Gregory JW, Ophthalmology 2004 111 2 389 395 10.1016/S0161-6420(03)00833-9 15019396 (Pubitemid 38183251)
6. Hemangiomas: new insight and medical treatment. Neri I, Balestri R, Patrizi A, Dermatol Ther 2012 25 4 322 334 10.1111/j.1529-8019.2012.01481.x 22950559
7. Growth characteristics of infantile hemangiomas: implications for management. Chang LC, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, et al. Pediatrics 2008 122 2 360 367 10.1542/peds.2007-2767 18676554
8. RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to 24-week-olds. Chan H, McKay C, Adams S, Wargon O, Pediatrics 2013 131 6 1739 e1747 10.1542/peds.2012-3828 23650294
9. Effect of propranolol vs prednisolone vs propranolol with prednisolone in the management of infantile hemangioma: a randomized controlled study. Malik MA, Menon P, Rao KL, Samujh R, J Pediatr Surg 2013 48 12 2453 2459 10.1016/j.jpedsurg.2013.08.020 24314186
10. A randomized controlled trial of propranolol for infantile hemangiomas. Hogeling M, Adams S, Wargon O, Pediatrics 2011 128 2 259 e266 10.1542/peds.2010-0029 21788220
11. Propranolol for severe hemangiomas of infancy. Leaute-Labreze C, Dumas DLRE, Hubiche T, Boralevi F, Thambo JB, Taieb A, N Engl J Med 2008 358 24 2649 2651 10.1056/NEJMc0708819 18550886 (Pubitemid 351831393)
12. Propranolol-resistant infantile haemangiomas. Causse S, Aubert H, Saint-Jean M, Puzenat E, Bursztejn AC, Eschard C, Mahe E, Maruani A, Mazereeuw-Hautier J, Dreyfus I, et al. Br J Dermatol 2013 169 1 125 129 10.1111/bjd.12417 23659587
13. Late rebound of infantile hemangioma after cessation of oral propranolol. Shehata N, Powell J, Dubois J, Hatami A, Rousseau E, Ondrejchak S, McCuaig C, Pediatr Dermatol 2013 30 5 587 591 10.1111/pde.12190 24016283
14. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Mulliken JB, Glowacki J, Plast Reconstr Surg 1982 69 3 412 422 10.1097/00006534-198203000-00002 7063565 (Pubitemid 12191292)
15. Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. Khan ZA, Boscolo E, Picard A, Psutka S, Melero-Martin JM, Bartch TC, Mulliken JB, Bischoff J, J Clin Invest 2008 118 7 2592 2599 18535669 (Pubitemid 351949786)
16. Mesenchymal stem cells and adipogenesis in hemangioma involution. Yu Y, Fuhr J, Boye E, Gyorffy S, Soker S, Atala A, Mulliken JB, Bischoff J, Stem Cells 2006 24 6 1605 1612 10.1634/stemcells.2005-0298 16456130 (Pubitemid 44464678)
17. Endothelial progenitor cells in infantile hemangioma. Yu Y, Flint AF, Mulliken JB, Wu JK, Bischoff J, Blood 2004 103 4 1373 1375 14576053 (Pubitemid 38168651)
18. In vitro characteristics of neonatal hemangioma endothelial cells: similarities and differences between normal neonatal and fetal endothelial cells. Dosanjh A, Chang J, Bresnick S, Zhou L, Reinisch J, Longaker M, Karasek M, J Cutan Pathol 2000 27 9 441 450 10.1034/j.1600-0560.2000.027009441.x 11028814
19. Mesenchymal stem cells in infantile hemangioma reside in the perivascular region. Yuan SM, Chen RL, Shen WM, Chen HN, Zhou XJ, Pediatr Dev Pathol 2012 15 1 5 12 10.2350/11-01-0959-OA.1 21689017
20. Isolation, characterization, and in vitro propagation of infantile hemangioma stem cells and an in vivo mouse model. Xu D, TM O, Shartava A, Fowles TC, Yang J, Fink LM, Ward DC, Mihm MC, Waner M, Ma Y, J Hematol Oncol 2011 4 54 10.1186/1756-8722-4-54 22192404
21. Corticosteroid suppression of VEGF-A in infantile hemangioma-derived stem cells. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J, N Engl J Med 2010 362 11 1005 1013 10.1056/NEJMoa0903036 20237346
22. CD133 selected stem cells from proliferating infantile hemangioma and establishment of an in vivo mice model of hemangioma. Mai HM, Zheng JW, Wang YA, Yang XJ, Zhou Q, Qin ZP, Li KL, Chin Med J (Engl) 2013 126 1 88 94 23286484
23. CD133: a stem cell biomarker and beyond. Li Z, Exp Hematol Oncol 2013 2 1 17 10.1186/2162-3619-2-17 23815814
24. Pathogenesis of infantile haemangioma. Greenberger S, Bischoff J, Br J Dermatol 2013 169 1 12 19 10.1111/bjd.12435 23668474
25. Vasculogenesis in infantile hemangioma. Boscolo E, Bischoff J, Angiogenesis 2009 12 2 197 207 10.1007/s10456-009-9148-2 19430954
26. The role of vascular endothelial growth factor (VEGF) in tumor angiogenesis and early clinical development of VEGF-receptor kinase inhibitors. Verheul HM, Pinedo HM, Clin Breast Cancer 2000 1 Suppl 1 80 S84 11970755
27. Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. Przewratil P, Sitkiewicz A, Andrzejewska E, Cytokine 2010 49 2 141 147 10.1016/j.cyto.2009.11.012 20015661
28. Circulating level of vascular endothelial growth factor in differentiating hemangioma from vascular malformation patients. Zhang L, Lin X, Wang W, Zhuang X, Dong J, Qi Z, Hu Q, Plast Reconstr Surg 2005 116 1 200 204 10.1097/01.PRS.0000170804.80834.5F 15988268 (Pubitemid 40944039)
29. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Shibuya M, Angiogenesis 2006 9 4 225 230 231 10.1007/s10456-006-9055-8 17109193
30. Endothelial cell apoptosis in angiogenesis and vessel regression. Dimmeler S, Zeiher AM, Circ Res 2000 87 6 434 439 10.1161/01.RES.87.6.434 10988233
31. Co-expression of VEGF-C and its receptors, VEGFR-2 and VEGFR-3, in endothelial cells of lymphangioma. Implication in autocrine or paracrine regulation of lymphangioma. Huang HY, Ho CC, Huang PH, Hsu SM, Lab Invest 2001 81 12 1729 1734 10.1038/labinvest.3780386 11742043
32. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. Shawber CJ, Funahashi Y, Francisco E, Vorontchikhina M, Kitamura Y, Stowell SA, Borisenko V, Feirt N, Podgrabinska S, Shiraishi K, et al. J Clin Invest 2007 117 11 3369 3382 10.1172/JCI24311 17948123 (Pubitemid 350096993)
33. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, Moudry P, Bartek JJ, Fischer W, Lukas J, et al. J Exp Med 2012 209 3 507 520 10.1084/jem.20111424 22393126
34. VEGF receptor signalling-in control of vascular function. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, Nat Rev Mol Cell Biol 2006 7 5 359 371 10.1038/nrm1911 16633338
35. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Gupta K, Kshirsagar S, Li W, Gui L, Ramakrishnan S, Gupta P, Law PY, Hebbel RP, Exp Cell Res 1999 247 2 495 504 10.1006/excr.1998.4359 10066377 (Pubitemid 29394787)
36. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N, J Biol Chem 1998 273 46 30336 30343 10.1074/jbc.273.46.30336 9804796 (Pubitemid 28545503)
37. The biology of VEGF and its receptors. Ferrara N, Gerber HP, LeCouter J, Nat Med 2003 9 6 669 676 10.1038/nm0603-669 12778165 (Pubitemid 36749215)
38. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N, Nature 2002 417 6892 954 958 10.1038/nature00821 12087404 (Pubitemid 34716872)
39. Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. Medici D, Olsen BR, PLoS One 2012 7 8 42913 10.1371/journal.pone.0042913 22900063
40. Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR, Nat Med 2008 14 11 1236 1246 10.1038/nm.1877 18931684
41. Somatic mutation of vascular endothelial growth factor receptors in juvenile hemangioma. Walter JW, North PE, Waner M, Mizeracki A, Blei F, Walker JW, Reinisch JF, Marchuk DA, Genes Chromosomes Cancer 2002 33 3 295 303 10.1002/gcc.10028 11807987 (Pubitemid 34130936)
42. Pericytes from infantile hemangioma display proangiogenic properties and dysregulated angiopoietin-1. Boscolo E, Mulliken JB, Bischoff J, Arterioscler Thromb Vasc Biol 2013 33 3 501 509 10.1161/ATVBAHA.112.300929 23288163
43. JAGGED1 signaling regulates hemangioma stem cell-to-pericyte/vascular smooth muscle cell differentiation. Boscolo E, Stewart CL, Greenberger S, Wu JK, Durham JT, Herman IM, Mulliken JB, Kitajewski J, Bischoff J, Arterioscler Thromb Vasc Biol 2011 31 10 2181 2192 10.1161/ATVBAHA.111.232934 21757656
44. A switch in Notch gene expression parallels stem cell to endothelial transition in infantile hemangioma. Wu JK, Adepoju O, De Silva D, Baribault K, Boscolo E, Bischoff J, Kitajewski J, Angiogenesis 2010 13 1 15 23 10.1007/s10456-009-9161-5 20069356
45. COSMC is overexpressed in proliferating infantile hemangioma and enhances endothelial cell growth via VEGFR2. Lee JJ, Chen CH, Chen YH, Huang MJ, Huang J, Hung JS, Chen MT, Huang MC, PLoS One 2013 8 2 56211 10.1371/journal.pone. 0056211 23424651
46. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M, Cell 2010 140 2 268 279 10.1016/j.cell.2009.12.046 20141840
47. Autocrine VEGF signaling is required for vascular homeostasis. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML, Cell 2007 130 4 691 703 10.1016/j.cell.2007.06.054 17719546 (Pubitemid 47268059)
48. Upregulated autocrine vascular endothelial growth factor (VEGF)/VEGF receptor-2 loop prevents apoptosis in haemangioma-derived endothelial cells. Ji Y, Chen S, Li K, Xiao X, Xu T, Zheng S, Br J Dermatol 2014 170 1 78 86 10.1111/bjd.12592 24033364
49. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Franco M, Roswall P, Cortez E, Hanahan D, Pietras K, Blood 2011 118 10 2906 2917 10.1182/blood-2011-01-331694 21778339
50. Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Kearney JB, Ambler CA, Monaco KA, Johnson N, Rapoport RG, Bautch VL, Blood 2002 99 7 2397 2407 10.1182/blood.V99.7.2397 11895772 (Pubitemid 34525425)
51. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Fong GH, Rossant J, Gertsenstein M, Breitman ML, Nature 1995 376 6535 66 70 10.1038/376066a0 7596436
52. Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Calicchio ML, Collins T, Kozakewich HP, Am J Pathol 2009 174 5 1638 1649 10.2353/ajpath.2009. 080517 19349369
53. VEGFR-1 mediates endothelial differentiation and formation of blood vessels in a murine model of infantile hemangioma. Boscolo E, Mulliken JB, Bischoff J, Am J Pathol 2011 179 5 2266 2277 10.1016/j.ajpath.2011.07.040 21945324
54. Notch signaling in vascular development. Iso T, Hamamori Y, Kedes L, Arterioscler Thromb Vasc Biol 2003 23 4 543 553 10.1161/01.ATV.0000060892.81529. 8F 12615665 (Pubitemid 36438065)
55. Notch signaling during vascular development. Gridley T, Proc Natl Acad Sci U S A 2001 98 10 5377 5378 10.1073/pnas.101138098 11344278 (Pubitemid 32435650)
56. Expression of HES and HEY genes in infantile hemangiomas. Adepoju O, Wong A, Kitajewski A, Tong K, Boscolo E, Bischoff J, Kitajewski J, Wu JK, Vasc Cell 2011 3 19 10.1186/2045-824X-3-19 21834989
57. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Dufraine J, Funahashi Y, Kitajewski J, Oncogene 2008 27 38 5132 5137 10.1038/onc.2008.227 18758482
58. Functional arterial and venous fate is determined by graded VEGF signaling and notch status during embryonic stem cell differentiation. Lanner F, Sohl M, Farnebo F, Arterioscler Thromb Vasc Biol 2007 27 3 487 493 10.1161/01.ATV.0000255990.91805.6d 17185616
59. Notch signaling from tumor cells: a new mechanism of angiogenesis. Li JL, Harris AL, Cancer Cell 2005 8 1 1 3 10.1016/j.ccr.2005.06.013 16023591 (Pubitemid 40991807)
60. Notch signaling is essential for vascular morphogenesis in mice. Krebs LT, Xue Y, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, et al. Genes Dev 2000 14 11 1343 1352 10837027 (Pubitemid 30397078)
61. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Xue Y, Gao X, Lindsell CE, Norton CR, Chang B, Hicks C, Gendron-Maguire M, Rand EB, Weinmaster G, Gridley T, Hum Mol Genet 1999 8 5 723 730 10.1093/hmg/8.5.723 10196361 (Pubitemid 29189039)
62. The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Hainaud P, Contreres JO, Villemain A, Liu LX, Plouet J, Tobelem G, Dupuy E, Cancer Res 2006 66 17 8501 8510 10.1158/0008-5472.CAN-05-4226 16951162 (Pubitemid 44449163)
63. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW, Harris AL, Cancer Res 2005 65 19 8690 8697 10.1158/0008-5472.CAN-05-1208 16204037 (Pubitemid 41377356)
64. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G, Nature 2006 444 7122 1032 1037 10.1038/nature05355 17183313 (Pubitemid 46018516)
65. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Williams CK, Li JL, Murga M, Harris AL, Tosato G, Blood 2006 107 3 931 939 16219802 (Pubitemid 43156289)
66. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. Zhang J, Ye J, Ma D, Liu N, Wu H, Yu S, Sun X, Tse W, Ji C, Carcinogenesis 2013 34 3 667 677 10.1093/carcin/bgs386 23239744
67. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, et al. Nature 2007 445 7129 776 780 10.1038/nature05571 17259973 (Pubitemid 46279716)
68. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, Adams RH, Cell 2009 137 6 1124 1135 10.1016/j.cell.2009.03.025 19524514
69. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, Chen H, Jenner R, Herbolsheimer E, Jacobsen E, et al. Proc Natl Acad Sci U S A 2005 102 12 4459 4464 10.1073/pnas.0501076102 15753290 (Pubitemid 40397134)
70. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della RG, Lin F, Kawakatsu H, Owada K, Luttrell DK, et al. Science 1999 283 5402 655 661 10.1126/science.283.5402.655 9924018 (Pubitemid 29074997)
71. beta-blockers: a novel class of antitumor agents. Ji Y, Chen S, Xiao X, Zheng S, Li K, Onco Targets Ther 2012 5 391 401 23226026
72. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, et al. J Biol Chem 2010 285 46 35462 35470 10.1074/jbc.M110.109579 20826776
73. Stress hormones increase cell proliferation and regulates interleukin-6 secretion in human oral squamous cell carcinoma cells. Bernabe DG, Tamae AC, Biasoli ER, Oliveira SH, Brain Behav Immun 2011 25 3 574 583 10.1016/j.bbi.2010.12.012 21187140
74. Computational identification of gene-social environment interaction at the human IL6 locus. Cole SW, Arevalo JM, Takahashi R, Sloan EK, Lutgendorf SK, Sood AK, Sheridan JF, Seeman TE, Proc Natl Acad Sci U S A 2010 107 12 5681 5686 10.1073/pnas.0911515107 20176930
75. Catecholamines regulate tumor angiogenesis. Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S, Cancer Res 2009 69 9 3727 3730 10.1158/0008-5472.CAN- 08-4289 19383906
76. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, et al. Nat Med 2006 12 8 939 944 10.1038/nm1447 16862152 (Pubitemid 44175146)
77. beta-blockers increase response to chemotherapy via direct antitumour and anti-angiogenic mechanisms in neuroblastoma. Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris MD, Trahair T, Andre N, Kavallaris M, Br J Cancer 2013 108 12 2485 2494 10.1038/bjc.2013.205 23695022
78. Comment on 'Beta-blockers increase response to chemotherapy via direct anti-tumour and anti-angiogenic mechanisms in neuroblastoma'. Ji Y, Chen S, Br J Cancer 2013 109 7 2022 2023 10.1038/bjc.2013.497 23969727
79. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Entschladen F, Drell TT, Lang K, Joseph J, Zaenker KS, Lancet Oncol 2004 5 4 254 258 10.1016/S1470-2045(04)01431-7 15050959 (Pubitemid 38391223)
80. Stress hormone-mediated invasion of ovarian cancer cells. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW, Clin Cancer Res 2006 12 2 369 375 10.1158/1078-0432.CCR-05-1698 16428474 (Pubitemid 43166123)
81. Src activation by beta-adrenoreceptors is a key switch for tumour metastasis. Armaiz-Pena GN, Allen JK, Cruz A, Stone RL, Nick AM, Lin YG, Han LY, Mangala LS, Villares GJ, Vivas-Mejia P, et al. Nat Commun 2013 4 1403 23360994
82. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. Sastry KS, Karpova Y, Prokopovich S, Smith AJ, Essau B, Gersappe A, Carson JP, Weber MJ, Register TC, Chen YQ, et al. J Biol Chem 2007 282 19 14094 14100 10.1074/jbc.M611370200 17353197 (Pubitemid 47100469)
83. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, et al. J Clin Invest 2010 120 5 1515 1523 10.1172/JCI40802 20389021
84. Behavioral stress accelerates prostate cancer development in mice. Hassan S, Karpova Y, Baiz D, Yancey D, Pullikuth A, Flores A, Register T, Cline JM, D'Agostino RJ, Danial N, et al. J Clin Invest 2013 123 2 874 886 23348742
85. Effects of propranolol on the proliferation and apoptosis of hemangioma-derived endothelial cells. Ji Y, Li K, Xiao X, Zheng S, Xu T, Chen S, J Pediatr Surg 2012 47 12 2216 2223 10.1016/j.jpedsurg.2012.09.008 23217879
86. A stress response pathway regulates DNA damage through beta2-adrenoreceptors and beta-arrestin-1. Hara MR, Kovacs JJ, Whalen EJ, Rajagopal S, Strachan RT, Grant W, Towers AJ, Williams B, Lam CM, Xiao K, et al. Nature 2011 477 7364 349 353 10.1038/nature10368 21857681
87. Stress-induced immune dysfunction: implications for health. Glaser R, Kiecolt-Glaser JK, Nat Rev Immunol 2005 5 3 243 251 10.1038/nri1571 15738954 (Pubitemid 40364825)
88. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Goldfarb Y, Sorski L, Benish M, Levi B, Melamed R, Ben-Eliyahu S, Ann Surg 2011 253 4 798 810 10.1097/SLA.0b013e318211d7b5 21475023
89. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor. Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, Meiboom H, Ben-Eliyahu S, J Immunol 2010 184 5 2449 2457 10.4049/jimmunol.0903301 20124103
90. Do antihypertensive medications influence breast cancer risk? Ji Y, Chen S, JAMA Intern Med 2014 In press
91. Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol. Pope E, Chakkittakandiyil A, Lara-Corrales I, Maki E, Weinstein M, Br J Dermatol 2013 168 1 222 224 10.1111/j.1365-2133.2012.11131.x 22762503
92. Targeted therapies: using beta-blockers to inhibit breast cancer progression. Powe DG, Entschladen F, Nat Rev Clin Oncol 2011 8 9 511 512 10.1038/nrclinonc.2011.123 21808268
93. High levels of beta2-adrenoceptors are expressed in infantile capillary hemangiomas and may mediate the therapeutic effect of propranolol. Hadaschik E, Scheiba N, Engstner M, Flux K, J Cutan Pathol 2012 39 9 881 883 10.1111/j.1600-0560.2012.01937.x 22764832
94. beta-Adrenergic receptor expression in vascular tumors. Chisholm KM, Chang KW, Truong MT, Kwok S, West RB, Heerema-McKenney AE, Mod Pathol 2012 25 11 1446 1451 10.1038/modpathol.2012.108 22743651
95. beta1-Adrenoceptor mRNA level reveals distinctions between infantile hemangioma and vascular malformations. Rossler J, Haubold M, Gilsbach R, Juttner E, Schmitt D, Niemeyer CM, Hein L, Pediatr Res 2013 73 4 Pt 1 409 413 23370410
96. The role of beta-adrenergic receptor signaling in the proliferation of hemangioma-derived endothelial cells. Ji Y, Chen S, Li K, Xiao X, Zheng S, Xu T, Cell Div 2013 8 1 1 10.1186/1747-1028-8-1 23286511
97. Tocolysis with the beta-2-sympathomimetic hexoprenaline increases occurrence of infantile haemangioma in preterm infants. Mayer M, Minichmayr A, Klement F, Hroncek K, Wertaschnigg D, Arzt W, Wiesinger-Eidenberger G, Lechner E, Arch Dis Child Fetal Neonatal Ed 2013 98 2 108 F111 10.1136/archdischild- 2011-301030 22611112
98. Propranolol: a novel anti-hemangioma agent with multiple potential mechanisms of action. Ji Y, Chen S, Li K, Xiao X, Zheng S, Ann Surg 2013 In press
99. Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2. Kim KT, Choi HH, Steinmetz MO, Maco B, Kammerer RA, Ahn SY, Kim HZ, Lee GM, Koh GY, J Biol Chem 2005 280 20 20126 20131 10.1074/jbc.M500292200 15769741 (Pubitemid 41379543)
100. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly R, Alitalo K, Dumont DJ, J Biol Chem 1999 274 43 30896 30905 10.1074/jbc.274.43.30896 10521483 (Pubitemid 29503927)
101. A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Jones N, Chen SH, Sturk C, Master Z, Tran J, Kerbel RS, Dumont DJ, Mol Cell Biol 2003 23 8 2658 2668 10.1128/MCB.23.8.2658-2668.2003 12665569 (Pubitemid 36403068)
102. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. Jeansson M, Gawlik A, Anderson G, Li C, Kerjaschki D, Henkelman M, Quaggin SE, J Clin Invest 2011 121 6 2278 2289 10.1172/JCI46322 21606590
103. Orchestral actions of angiopoietin-1 in vascular regeneration. Koh GY, Trends Mol Med 2013 19 1 31 39 10.1016/j.molmed.2012.10.010 23182855
104. Increased Tie2 expression, enhanced response to angiopoietin-1, and dysregulated angiopoietin-2 expression in hemangioma-derived endothelial cells. Yu Y, Varughese J, Brown LF, Mulliken JB, Bischoff J, Am J Pathol 2001 159 6 2271 2280 10.1016/S0002-9440(10)63077-5 11733376 (Pubitemid 33104280)
105. Signaling mechanisms in infantile hemangioma. Boye E, Olsen BR, Curr Opin Hematol 2009 16 3 202 208 10.1097/MOH.0b013e32832a07ff 19367160
106. Infantile hemangiomas: an update on pathogenesis and therapy. Chen TS, Eichenfield LF, Friedlander SF, Pediatrics 2013 131 1 99 108 10.1542/peds.2012-1128 23266916
107. Myeloid cells in infantile hemangioma. Ritter MR, Reinisch J, Friedlander SF, Friedlander M, Am J Pathol 2006 168 2 621 628 10.2353/ajpath.2006.050618 16436675 (Pubitemid 43271159)
108. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Kleinman ME, Greives MR, Churgin SS, Blechman KM, Chang EI, Ceradini DJ, Tepper OM, Gurtner GC, Arterioscler Thromb Vasc Biol 2007 27 12 2664 2670 10.1161/ATVBAHA.107.150284 17872454 (Pubitemid 350158920)
109. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Storch CH, Hoeger PH, Br J Dermatol 2010 163 2 269 274 10.1111/j.1365-2133.2010.09848.x 20456345
110. Propranolol induces regression of hemangioma cells through HIF-1alpha-mediated inhibition of VEGF-A. Chim H, Armijo BS, Miller E, Gliniak C, Serret MA, Gosain AK, Ann Surg 2012 256 1 146 156 10.1097/SLA. 0b013e318254ce7a 22580939
111. Hypoxia-induced autophagy in endothelial cells: a double-edged sword in the progression of infantile haemangioma? Chen G, Zhang W, Li YP, Ren JG, Xu N, Liu H, Wang FQ, Sun ZJ, Jia J, Zhao YF, Cardiovasc Res 2013 98 3 437 448 10.1093/cvr/cvt035 23408345
112. Rapalogs and mTOR inhibitors as anti-aging therapeutics. Lamming DW, Ye L, Sabatini DM, Baur JA, J Clin Invest 2013 123 3 980 989 10.1172/JCI64099 23454761
113. Rapamycin passes the torch: a new generation of mTOR inhibitors. Benjamin D, Colombi M, Moroni C, Hall MN, Nat Rev Drug Discov 2011 10 11 868 880 10.1038/nrd3531 22037041
114. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Slomovitz BM, Coleman RL, Clin Cancer Res 2012 18 21 5856 5864 10.1158/1078-0432.CCR-12-0662 23082003
115. Rapamycin suppresses self-renewal and vasculogenic potential of stem cells isolated from infantile hemangioma. Greenberger S, Yuan S, Walsh LA, Boscolo E, Kang KT, Matthews B, Mulliken JB, Bischoff J, J Invest Dermatol 2011 131 12 2467 2476 10.1038/jid.2011.300 21938011
116. Genetic mapping of a novel familial form of infantile hemangioma. Walter JW, Blei F, Anderson JL, Orlow SJ, Speer MC, Marchuk DA, Am J Med Genet 1999 82 1 77 83 10.1002/(SICI)1096-8628(19990101)82:1<77::AID-AJMG15>3.0.CO;2-A 9916848 (Pubitemid 29022304)
117. Endothelium-specific ablation of PDGFB leads to pericyte loss and glomerular, cardiac and placental abnormalities. Bjarnegard M, Enge M, Norlin J, Gustafsdottir S, Fredriksson S, Abramsson A, Takemoto M, Gustafsson E, Fassler R, Betsholtz C, Development 2004 131 8 1847 1857 10.1242/dev.01080 15084468 (Pubitemid 38559851)
118. Endothelial-derived PDGF-BB and HB-EGF coordinately regulate pericyte recruitment during vasculogenic tube assembly and stabilization. Stratman AN, Schwindt AE, Malotte KM, Davis GE, Blood 2010 116 22 4720 4730 10.1182/blood-2010-05-286872 20739660
119. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM, Cancer Res 2007 67 15 7358 7367 10.1158/0008-5472.CAN-07-0293 17671206 (Pubitemid 47206566)
120. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. Pietras K, Hanahan D, J Clin Oncol 2005 23 5 939 952 15557593 (Pubitemid 46202314)
121. Intrinsic regulation of hemangioma involution by platelet-derived growth factor. Roach EE, Chakrabarti R, Park NI, Keats EC, Yip J, Chan NG, Khan ZA, Cell Death Dis 2012 3 328 10.1038/cddis.2012.58 22717583
122. The effects of PTK787/ZK222584, an inhibitor of VEGFR and PDGFRbeta pathways, on intussusceptive angiogenesis and glomerular recovery from Thy1.1 nephritis. Wnuk M, Hlushchuk R, Tuffin G, Huynh-Do U, Djonov V, Am J Pathol 2011 178 4 1899 1912 10.1016/j.ajpath.2010.12.049 21435466
123. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. Erber R, Thurnher A, Katsen AD, Groth G, Kerger H, Hammes HP, Menger MD, Ullrich A, Vajkoczy P, Faseb J 2004 18 2 338 340 14657001